Excavations reveal Roman site of major importance

We use cookies to ensure that we give you the best experience on our website. You can change your cookie settings at any time. Otherwise, we'll assume you're OK to continue. Durham University spin-out in deal to develop potential prostate cancer test A Durham University spin-out company has signed a deal to enable the development of technology that could improve the diagnosis of prostate cancer in the future. FScan Ltd has agreed a worldwide exclusive licensing deal with Glide Pharma which will see the Oxfordshire based company exploit its lanthanide technology that uses light energy to measure the level of citrate in seminal fluid samples. The level of citrate can be used to signal the onset and progression of prostate cancer. The technology was developed by Professor David Parker and Dr Robert Pal working in Durham University's Department of Chemistry , where David has been a Professor since 1992.